Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neo-TN: Individualized Neoadjuvant Chemotherapy in TNBC
NCT01057069Phase 3Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2010
- Primary completion
- Jun 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of carboplatin, thiotepa, cyclophosphamide in triple-negative breast cancer (TNBC), sponsored by Netherlands Cancer Institute. Started Jan 2010; status: active, not recruiting.
02
Drugs
carboplatinthiotepacyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01057069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01057069.